US › Healthcare

Kyntra Bio, Inc. (KYNB)

US · Healthcare · Biotechnology

$4.85-9.51%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$-1.5M

Revenue YoY

-209.3%

Net profit

$12.0M

EPS

$-4.68

EPS estimate

$-3.18

EPS came in at -4.68 against a street estimate of -3.18 — a miss of 47.2%.

Key statistics

Market cap

$24.7M

Forward P/E

61.3

P/B

80.40

Book value

$-7.45

EPS (TTM)

$-7.64

52-week high

$11.65

52-week low

$5.62

50-day MA

$7.27

200-day MA

$7.41

Beta

1.05

Analyst view

Analysts rate Kyntra Bio, Inc. a strong buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $39.67.

Shareholding

Insiders

2.02%

Institutions

24.68%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	9.88%
Vanguard Capital Management, LLC	3.95%
Acadian Asset Management LLC	2.61%
BlackRock Inc	2.08%
Geode Capital Management, LLC	1.07%
HighTower Advisors, LLC	0.98%
Two Sigma Investments LLC	0.98%
Renaissance Technologies Corp	0.67%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kyntra Bio, Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.